Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acqui
SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
10:10am, Monday, 23'rd Mar 2026
LOS ANGELES, March 23, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc.
SHAREHOLDER ALERT: Berger Montague Reminds Ultragenyx Pharmaceutical Inc. (RARE) Investors of a Class Action Lawsuit Deadline
09:06am, Monday, 23'rd Mar 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical
New class action for Ultragenyx (RARE) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/6/2026.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acqui
NEW YORK, March 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August
NEW ORLEANS, March 20, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securiti
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 20'th Mar 2026
NOVATO, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ra
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acqui
NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE).
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
08:09pm, Thursday, 19'th Mar 2026
NEW YORK, March 19, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3,
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
10:40am, Thursday, 19'th Mar 2026
LOS ANGELES, March 19, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc.
NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such
SAN DIEGO, March 19, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and De
